Fig. 1 · Structure

Documents & Downloads

Cevimeline (AF-102B)

Cat. No. A11372 CAS 107233-08-9

M1/M3 receptor agonist

Cevimeline (AF-102B) is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors; used in the treatment of dry mouth associated with sjogren's syndrome.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Cevimeline (AF-102B) Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Cevimeline (AF-102B) from 3 published references.

Cevimeline (AF-102B) In Vitro Studies

Wildtype cells were treated with Cevimeline at 100–500 μM. Treatment was associated with a significant increase in cilia length compared with the vehicle-treated group. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Increased cilia length in wildtype cells

Cell-based study · wildtype cells [1]

Wildtype cells were treated with Cevimeline at 100–500 μM. Treatment was associated with a significant increase in cilia length compared with the vehicle-treated group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cilia lengthReported result cevimeline treatment was associated with a significant increase in cilia length[1]

Literature-Reported Treatment Conditions

Treatment concentration
100–500 μM
Reported limits
Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Cevimeline

Evidence for Cevimeline as the hydrochloride form reported in the paper, not the free base/neutral form supplied as A11372; no salt equivalence, dose conversion or lot validation.

Results > CHRM3 modulation alters cilia length and sensory function (S24); Fig. 2 legend (S208)

cilia length: cilia length; comparator: vehicle-treated group — Results > CHRM3 modulation alters cilia length and sensory function (S24)

Cevimeline (AF-102B) In Vivo Studies

In female Sprague Dawley rats, Cevimeline at 27 mg/kg/day for 9 weeks significantly decreased BMI compared with vehicle control (p < 0.05). TC concentration was significantly lower in both the Cevimeline-only group and the OLZ + CEV group compared with control (p < 0.01). In albino rats receiving MTX, oral Cevimeline at 10 mg/kg daily for 9 days was evaluated with the MTX group as the comparison to isolate the compound effect. The MTX + CVM group had a reported Caspase 3 stained-area readout of 31.09 ± 5.90. [2,3]

BMI reduction in female Sprague Dawley rats

Animal study · female Sprague Dawley rats; n = 12/group [2]

Female Sprague Dawley rats received Cevimeline at 27 mg/kg/day for 9 weeks. BMI decreased significantly compared with the vehicle control (p < 0.05).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
BMI valueReported result a significant decrease in the Cevimeline group (vs. control, p < 0.05)[2]

Conditions shared by the study groups

Treatment course
t.i.d.; 9 weeks
Vehicle
0.6 g cookie dough
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cevimeline 27 mg/kg/dayvehicle (0.6 g cookie dough without drugs, control)a significant decrease in the Cevimeline group (vs. control, p < 0.05)[2]
Cevimeline 27 mg/kg/day
Model: female Sprague Dawley rats; n = 12/group
Reported limits: Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Cevimeline

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Animal Experimental Design (S1, S10); 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S45)

BMI value: BMI value; comparator: vehicle (0.6 g cookie dough without drugs, control) — 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S45)

Cevimeline 27 mg/kg/day · 2. Materials and Methods > 2.1. Animal Experimental Design (S10); 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S45)

Caspase staining in albino rats receiving MTX and Cevimeline

Animal study · albino rats; MTX + CVM group included 25 rats [3]

Albino rats in the MTX + CVM group received oral Cevimeline at 10 mg/kg daily for 9 days, with MTX at 20 mg/kg as another intervention. The reported Caspase 3 stained-area readout was 31.09 ± 5.90 for the MTX + CVM group, with the MTX group serving as the comparison to isolate the compound effect.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Caspase 3; percentage of stained areaReported result 31.09 ± 5.90[3]

Conditions shared by the study groups

Route
taken orally
Treatment course
daily for 9 days
Vehicle
saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cevimeline 10 mg/kg25 rats that received 20 mg/kg MTX as a single intraperitoneal dose on day one and were maintained under observation for 9 days31.09 ± 5.90[3]
Cevimeline 10 mg/kg
Model: albino rats; MTX + CVM group included 25 rats
Reported limits: Removed after verification: value.
Methods and source locations

Compound reported in the paper: Cevimeline

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Experimental protocol (S10, S14); Materials and methods > Rat euthanasia and tissue preparation (S16, S21); Results > Caspase 3 immunohistochemical results (S33); Fig. 2 legend (S43); Table 1 legend (S55, S56); Table 1 (T1.r2, T1.r3)

Caspase 3; percentage of stained area: Caspase 3; percentage of stained area; comparator: 25 rats that received 20 mg/kg MTX as a single intraperitoneal dose on day one and were maintained under observation for 9 days — Materials and methods > Rat euthanasia and tissue preparation (S21); Results > Caspase 3 immunohistochemical results (S33); Fig. 2 legend (S43)

Cevimeline 10 mg/kg · Materials and methods > Experimental protocol (S14); Results > Caspase 3 immunohistochemical results (S33)

Lower TC concentration in female Sprague Dawley rats

Animal study · female Sprague Dawley rats; n = 12/group [2]

Female Sprague Dawley rats received Cevimeline at 27 mg/kg/day for 9 weeks. TC concentration was significantly lower in both the Cevimeline-only group and the OLZ + CEV group compared with control (p < 0.01).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TC concentrationReported result TC concentration was significantly lower in the rats that received only Cevimeline treatment and the rats that received OLZ + CEV treatment (both vs. control, p < 0.01; Figure 3D).[2]

Conditions shared by the study groups

Treatment course
t.i.d.; 9 weeks
Vehicle
0.6 g cookie dough
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cevimeline 27 mg/kg/dayvehicle (0.6 g cookie dough without drugs, control)TC concentration was significantly lower in the rats that received only Cevimeline treatment and the rats that received OLZ + CEV treatment (both vs. control, p < 0.01; Figure 3D).[2]
Cevimeline 27 mg/kg/day
Model: female Sprague Dawley rats; n = 12/group
Reported limits: Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Cevimeline

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Animal Experimental Design (S1, S10); 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S51)

TC concentration: TC concentration; comparator: vehicle (0.6 g cookie dough without drugs, control) — 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S51)

Cevimeline 27 mg/kg/day · 2. Materials and Methods > 2.1. Animal Experimental Design (S10); 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S51)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 107233-08-9
Applications

M1/M3 receptor agonist

Formula C10H17NOS
Molecular Weight 199.31
Synonyms AF102B
SMILES
C[C@H]1SC[C@@]2(CN3CCC2CC3)O1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Cevimeline (AF-102B) Research References

  1. [1] Saternos HC, Forero KV, Meqdad MA, et al. Muscarinic acetylcholine receptor 3 localized to primary endothelial cilia regulates blood pressure and cognition. Sci Rep (2025). PMID: 39885271 DOI: 10.1038/s41598-025-87212-3 Source material
  2. [2] Su Y, Cao C, Chen S, et al. Olanzapine Modulate Lipid Metabolism and Adipose Tissue Accumulation via Hepatic Muscarinic M3 Receptor-Mediated Alk-Related Signaling. Biomedicines (2024). PMID: 39061977 DOI: 10.3390/biomedicines12071403 Source material
  3. [3] Aboulfotoh MM. Effect of cevimeline and different concentration of gum arabic on parotid salivary gland function in methotrexate-induced xerostomia: a comparative study. BMC Oral Health (2024). PMID: 38807094 DOI: 10.1186/s12903-024-04374-8 Source material

Added to your cart

View Cart Checkout
Loading...